Chebli, Julio Maria Fonseca 
; Parra, Rogério Serafim ; Flores, Cristina; Moraes, Antonio Carlos; Nones, Rodrigo Bremer; Gomes, Tarcia Nogueira Ferreira; Perdomo, Ana Maria Bravo; Scapini, Gustavo; Zaltman, Cyrla
Source: Journal of Clinical Medicine. Unidade: FMRP
Subjects: RESULTADO DE TRATAMENTO, PROGRAMA DE ASSISTÊNCIA, DOENÇA DE CROHN
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
CHEBLI, Julio Maria Fonseca et al. Effectiveness and safety of ustekinumab for moderate to severely active Crohn’s disease: results from an early access program in Brazil. Journal of Clinical Medicine, v. 11, n. 21, 2022Tradução . . Disponível em: https://doi.org/10.3390/jcm11216481. Acesso em: 23 jan. 2026.APA
Chebli, J. M. F., Parra, R. S., Flores, C., Moraes, A. C., Nones, R. B., Gomes, T. N. F., et al. (2022). Effectiveness and safety of ustekinumab for moderate to severely active Crohn’s disease: results from an early access program in Brazil. Journal of Clinical Medicine, 11( 21). doi:10.3390/jcm11216481NLM
Chebli JMF, Parra RS, Flores C, Moraes AC, Nones RB, Gomes TNF, Perdomo AMB, Scapini G, Zaltman C. Effectiveness and safety of ustekinumab for moderate to severely active Crohn’s disease: results from an early access program in Brazil [Internet]. Journal of Clinical Medicine. 2022 ; 11( 21):[citado 2026 jan. 23 ] Available from: https://doi.org/10.3390/jcm11216481Vancouver
Chebli JMF, Parra RS, Flores C, Moraes AC, Nones RB, Gomes TNF, Perdomo AMB, Scapini G, Zaltman C. Effectiveness and safety of ustekinumab for moderate to severely active Crohn’s disease: results from an early access program in Brazil [Internet]. Journal of Clinical Medicine. 2022 ; 11( 21):[citado 2026 jan. 23 ] Available from: https://doi.org/10.3390/jcm11216481
